<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02319278</url>
  </required_header>
  <id_info>
    <org_study_id>2013-002336-24</org_study_id>
    <nct_id>NCT02319278</nct_id>
  </id_info>
  <brief_title>DEtection of Cellular Inflammation With FERumoxytol in the HEART</brief_title>
  <acronym>DECIFER</acronym>
  <official_title>DEtection of Cellular Inflammation With FERumoxytol in the HEART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Infirmary of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Golden Jubilee National Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To non-invasively image myocardial accumulation of ultrasmall superparamagnetic particles of
      iron oxide (USPIOs) by an increase in R2* values (compared to controls) within the myocardium
      of patients with:

      i. cardiac transplantation ii. acute myocarditis iii. suspected cardiac sarcoidosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ferumoxytol is a 'smart' magnetic resonance contrast agent consisting of ultrasmall
      superparamagnetic particles of iron oxide (USPIOs) that are taken up by macrophages.
      Concentration of USPIOs within macrophages changes the tissue relaxation properties and this
      can be detected by magnetic resonance imaging using R2* maps. In a recent early
      proof-of-concept study, we demonstrated that macrophages could be detected with USPIOs in the
      penumbra and infarct zone of the myocardium in patients with a recent myocardial infarction.
      The investigators therefore wish to establish whether USPIOs can be used to identify cellular
      inflammation within the myocardium in three distinct clinical conditions that currently lack
      a non-invasive diagnostic imaging test: cardiac allograft rejection, viral myocarditis and
      cardiac sarcoidosis. If successful, this would not only provide a useful diagnostic test but
      would also be a method of monitoring disease progression or response to therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Myocardial Cellular Inflammation.</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of Myocardial Cellular Inflammation through the increase in R2* value on post USPIO imaging versus baseline imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of R2* values with circulating inflammatory markers</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of circulating inflammatory markers in peripheral blood with myocardial inflammation (seen on cardiac R2* maps) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does clinical condition correlate with inflammation seen on R2* maps. (assessed by reduction in R2* values)</measure>
    <time_frame>1 year</time_frame>
    <description>Does treatment or recovery from these inflammatory myocardial conditions reduce or halt uptake of USPIOs as assessed by reduction in R2* values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Do higher R2* correlate with poorer outcome? (assessed by deterioration in ejection fraction or increase in late gadolinium enhancement)</measure>
    <time_frame>1 year</time_frame>
    <description>Do patients with higher R2* values have worse outcomes assessed by deterioration in ejection fraction or increase in late gadolinium enhancement.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Cardiac Transplant</condition>
  <condition>Cardiac Sarcoid</condition>
  <condition>Myocarditis</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Myocarditis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiac sarcoid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiac Transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol</intervention_name>
    <description>Infusion following between paired MRI scans</description>
    <arm_group_label>Myocarditis</arm_group_label>
    <arm_group_label>Cardiac sarcoid</arm_group_label>
    <arm_group_label>Cardiac Transplant</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. One of the four conditions below:

               -  Patients having undergone cardiac transplant

               -  Patients diagnosed clinically with myocarditis of any aetiology (eg viral,
                  septic, post chemotherapeutic etc)

               -  Patients clinically diagnosed with cardiac sarcoidosis

               -  Healthy volunteers

          2. Age &gt; 18 years.

        Exclusion Criteria:

          1. Contraindication to magnetic resonance imaging scanning identified from magnetic
             resonance imaging safety questionnaire

          2. Patients refusing or unable to give informed consent

          3. Renal failure (estimated glomerular filtration rate &lt;30 mL/min)

          4. Polycythemia

          5. Contraindication to ferumoxytol (previous allergic drug reaction, any immune or
             inflammatory conditions (eg, systemic lupus erythematosus, rheumatoid arthritis,
             history of severe asthma, eczema or other atopic allergy)), evidence of known iron
             overload, hemochromatosis, known hypersensitivity to ferumoxytol or its components or
             anaemia not caused by iron deficiency.

          6. Known allergy to dextran- or iron-containing compounds.

          7. Diagnosis of myocardial infarction within 1 month.

          8. Pregnancy or Breast-feeding.

          9. Women of child bearing age not ensuring reliable methods of contraception. Female
             participants of child bearing age will be asked if they are ensuring reliable methods
             of contraception prior to each administration of USPIO and MRI scan. If use of
             reliable contraception cannot be confirmed, the participant will be withdrawn.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Stirrat, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2014</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

